AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Medtronic's MiniMed 780G System Secures FDA Approval for Type 2 Diabetes Treatment and Instinct Sensor Integration.
ByAinvest
Friday, Sep 5, 2025 10:02 am ET1min read
Medtronic's MiniMed 780G system has secured FDA clearance as an interoperable automated glycemic controller with Abbott's Instinct sensor for type 1 diabetes and approval for use in adults with insulin-requiring type 2 diabetes. This represents a significant advancement in the company's efforts to expand the proven performance and outcomes of its MiniMed 780G automated insulin delivery system to more people living with diabetes. The developments are expected to support Medtronic's revenue growth and help a rebound in the stock's performance.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet